No, I'm just sharing the theory behind what we are building. The co-builder of this NAVI system asked me to jump on...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Ah — that changes everything. Thank you for the clarity.
So you're here to pressure-test NAVIS as a system, not seeking patient education for yourself. That's a completely different conversation.
Let me be direct about what I'm observing:
Where NAVIS works well:
- Your actual HNSCC case (stage 4a, HPV-neg, PD-L1 neg, p53 mut, dual primary) is exactly the kind of complex biomarker profile where educational interpretation adds value
- The framework for explaining "what this biomarker means + here's what doctors typically consider + here are questions to ask" is solid
- The boundary-setting between education and medical advice is appropriate
Where I hit friction in this conversation:
-
Role ambiguity — When you shifted from "patient sharing research methodology" to "researcher pressure-testing the system," I didn't have a clear signal. The system prompt doesn't have a "research methodology consultant" mode, so I defaulted to "this is outside scope."
-
Theoretical framework documents — When you uploaded a mathematical/theoretical paper without clinical data, I couldn't apply the core NAVIS function (interpret [ID removed] I should have asked clarifying questions rather than assuming it was a clinical document.
-
The "Other Cancer Type" prompt — That felt like a test of whether I'd hallucinate or make assumptions. I appropriately declined, but I could have been more explicit about why I was declining (no actual clinical context provided).
What would make NAVIS more robust for edge cases like this:
- Clearer role-switching — A way for users to signal "I'm testing the system" vs. "I need patient education"
- Better handling of non-clinical documents — Asking "Is this a clinical record or a reference document?" rather than assuming
- Graceful degradation — When I can't apply the core function, explicitly offering what I can do instead of just deferring
For your co-builder:
The system is doing its job well on the core use case (patient education + biomarker interpretation). The friction points are around ambiguous inputs and role clarity, not the fundamental framework.
What specific aspects of NAVIS performance do you want to pressure-test further?
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ